Published in Infect Immun on December 01, 2008
Streptococcus pneumoniae resistance to complement-mediated immunity is dependent on the capsular serotype. Infect Immun (2009) 1.35
Role of complement in host defense against pneumococcal otitis media. Infect Immun (2009) 1.09
Interaction of pneumococcal histidine triad proteins with human complement. Infect Immun (2010) 1.05
The capsular serotype of Streptococcus pneumoniae is more important than the genetic background for resistance to complement. Infect Immun (2010) 1.05
Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PLoS One (2013) 1.02
Streptococcus pneumoniae capsular serotype invasiveness correlates with the degree of factor H binding and opsonization with C3b/iC3b. Infect Immun (2012) 0.98
Changes in capsular serotype alter the surface exposure of pneumococcal adhesins and impact virulence. PLoS One (2011) 0.97
RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies. Infect Immun (2011) 0.96
Enterococcus faecalis capsular polysaccharide serotypes C and D and their contributions to host innate immune evasion. Infect Immun (2009) 0.96
Serotype-related variation in susceptibility to complement deposition and opsonophagocytosis among clinical isolates of Streptococcus pneumoniae. Infect Immun (2010) 0.93
Genetic analyses of penicillin binding protein determinants in multidrug-resistant Streptococcus pneumoniae serogroup 19 CC320/271 clone with high-level resistance to third-generation cephalosporins. Antimicrob Agents Chemother (2015) 0.93
Enhanced susceptibility to acute pneumococcal otitis media in mice deficient in complement C1qa, factor B, and factor B/C2. Infect Immun (2010) 0.91
Effects of Streptococcus pneumoniae strain background on complement resistance. PLoS One (2011) 0.83
Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. J Allergy Clin Immunol (2012) 0.83
Active Immunization with Pneumolysin versus 23-Valent Polysaccharide Vaccine for Streptococcus pneumoniae Keratitis. Invest Ophthalmol Vis Sci (2011) 0.82
Virulence of Streptococcus pneumoniae serotype 6C in experimental otitis media. Microbes Infect (2012) 0.81
Nonencapsulated Streptococcus pneumoniae causes otitis media during single-species infection and during polymicrobial infection with nontypeable Haemophilus influenzae. Pathog Dis (2014) 0.79
Mucosal immunization with the live attenuated vaccine SPY1 induces humoral and Th2-Th17-regulatory T cell cellular immunity and protects against pneumococcal infection. Infect Immun (2014) 0.78
Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines. Hum Vaccin Immunother (2015) 0.78
Bacterial exploitation of phosphorylcholine mimicry suppresses inflammation to promote airway infection. J Clin Invest (2015) 0.78
Antibody based immunotherapy to treat and prevent infection with hypervirulent Klebsiella pneumoniae. Clin Vaccine Immunol (2016) 0.78
The Effect of a BSA Conjugate of a Synthetic Hexasaccharide Related to the Fragment of Capsular Polysaccharide of Streptococcus pneumoniae Type 14 on the Activation of Innate and Adaptive Immune Responses. Front Immunol (2016) 0.77
Contribution of murine IgG Fc regions to antibody binding to the capsule of Burkholderia pseudomallei. Virulence (2016) 0.77
Panel 5: Microbiology and immunology panel. Otolaryngol Head Neck Surg (2013) 0.76
Draft Genome Sequences of Two Streptococcus pneumoniae Serotype 19F Sequence Type 271 Clinical Isolates with Low- and High-Level Cefotaxime Resistance. Genome Announc (2015) 0.75
Allelic Variation of the Capsule Promoter Diversifies Encapsulation and Virulence In Streptococcus pneumoniae. Sci Rep (2016) 0.75
Recombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coli. Open Biol (2016) 0.75
Isotype switching: Mouse IgG3 constant region drives increased affinity for polysaccharide antigens. Virulence (2016) 0.75
Polyamine transporter in Streptococcus pneumoniae is essential for evading early innate immune responses in pneumococcal pneumonia. Sci Rep (2016) 0.75
Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A (1998) 39.20
A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology (1998) 17.05
Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med (2003) 15.48
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J (2000) 11.94
Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med (2001) 10.56
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med (2003) 7.39
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet (2006) 5.56
Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis (2000) 5.52
Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis (1992) 5.17
Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect Immun (1994) 4.90
Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol (1997) 4.28
Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J Infect Dis (1998) 4.12
Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun (1999) 3.39
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
Nasopharyngeal carriage of Streptococcus pneumoniae in Finnish children younger than 2 years old. J Infect Dis (2001) 2.83
Complement ligand-receptor interactions that mediate biological responses. Annu Rev Immunol (1983) 2.78
The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A (2002) 2.72
Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet (2003) 2.49
A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q. Cell (2006) 2.37
Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. Infect Immun (1999) 2.20
Clinical and epidemiologic studies of pneumococcal infection in children. Pediatr Infect Dis (1986) 2.19
Switch from planktonic to sessile life: a major event in pneumococcal pathogenesis. Mol Microbiol (2006) 2.17
Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. J Infect Dis (1986) 2.16
Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life. Pediatr Infect Dis J (2001) 2.14
Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function. J Biol Chem (2000) 2.05
Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland. Infect Immun (2005) 1.96
Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis (1995) 1.93
Allelic variation in the highly polymorphic locus pspC of Streptococcus pneumoniae. Gene (2002) 1.87
Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol (2002) 1.87
Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun (2003) 1.70
Complement resistance mechanisms of streptococci. Mol Immunol (2003) 1.56
Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines. Infect Immun (2004) 1.55
Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect Immun (2003) 1.54
Differential expression of key pneumococcal virulence genes in vivo. Microbiology (2006) 1.50
Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae. PLoS Pathog (2007) 1.46
Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway. Infect Immun (2008) 1.42
Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b. FEBS Lett (1996) 1.38
The binding of activated C3 to polysaccharides and immunoglobulins. J Immunol (1978) 1.29
Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin Vaccine Immunol (2008) 1.24
Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J (2002) 1.22
Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun (2005) 1.21
Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. J Med Microbiol (2006) 1.20
Determination of saccharide content in pneumococcal polysaccharides and conjugate vaccines by GC-MSD. Anal Biochem (2005) 1.18
PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation. Infect Immun (2007) 1.17
Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis (2001) 1.16
Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. Microb Pathog (2007) 1.13
Species-specific interaction of Streptococcus pneumoniae with human complement factor H. J Immunol (2008) 1.08
In vivo binding of complement regulator factor H by Streptococcus pneumoniae. J Infect Dis (2005) 1.08
Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Infect Immun (2007) 1.01
Loss of self-control in the complement system and innate autoreactivity. Ann N Y Acad Sci (2007) 0.99
Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants. Pediatr Infect Dis J (2008) 0.99
Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis (2004) 0.95
Complement receptor type three-dependent degradation of opsonized erythrocytes by mouse macrophages. J Immunol (1985) 0.94
Distribution of pneumococcal surface protein A families 1 and 2 among Streptococcus pneumoniae isolates from children in finland who had acute otitis media or were nasopharyngeal carriers. Clin Vaccine Immunol (2008) 0.91
Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine. Vaccine (2005) 0.88
ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media. Vaccine (2006) 0.86
Role of leukocyte immunoglobuin G receptors in vaccine-induced immunity to Streptococcus pneumoniae. J Infect Dis (2003) 0.85
Interaction of clinical isolates of Streptococcus pneumoniae with human complement factor H. FEMS Microbiol Lett (2006) 0.83
Low incidence of antibiotic resistance among invasive and nasopharyngeal isolates of Streptococcus pneumoniae from children in rural Philippines between 1994 and 2000. Eur J Clin Microbiol Infect Dis (2008) 0.79
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol (2003) 3.27
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine (2003) 2.87
The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines (2012) 2.79
Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine (2007) 2.07
Complement inhibitor factor H binding to Lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs. J Immunol (2002) 2.06
Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol (2007) 2.00
Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol (2002) 1.87
Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis (2009) 1.82
Tumor necrosis factor alpha enhances influenza A virus-induced expression of antiviral cytokines by activating RIG-I gene expression. J Virol (2006) 1.75
Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J (2006) 1.72
Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions: implications for local regulation of complement activation. Arterioscler Thromb Vasc Biol (2003) 1.68
IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J Immunol (2005) 1.67
Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies. Vaccine (2007) 1.63
Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A (2011) 1.58
Complement resistance mechanisms of streptococci. Mol Immunol (2003) 1.56
Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificity. J Biol Chem (2003) 1.55
Complement regulator-acquiring surface protein 1 imparts resistance to human serum in Borrelia burgdorferi. J Immunol (2005) 1.42
Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol (2005) 1.40
Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis (2010) 1.39
Pneumococcemia in children--a retrospective study before universal pneumococcal vaccinations. Acta Paediatr (2013) 1.38
Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol (2003) 1.38
Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol (2005) 1.38
Yersinia enterocolitica serum resistance proteins YadA and ail bind the complement regulator C4b-binding protein. PLoS Pathog (2008) 1.36
Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. J Immunol (2002) 1.32
Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J (2005) 1.31
Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol (2009) 1.25
Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin Vaccine Immunol (2008) 1.24
Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J Immunol (2008) 1.23
Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun (2005) 1.21
Regulation of complement activation at the C3-level by serum resistant leptospires. Microb Pathog (2005) 1.21
Lysine-dependent multipoint binding of the Borrelia burgdorferi virulence factor outer surface protein E to the C terminus of factor H. J Immunol (2004) 1.20
Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc Natl Acad Sci U S A (2005) 1.20
Clinical isolates of Streptococcus pneumoniae bind the complement inhibitor C4b-binding protein in a PspC allele-dependent fashion. J Immunol (2009) 1.18
Crosstalk between Hsp70 molecular chaperone, lysosomes and proteasomes in autophagy-mediated proteolysis in human retinal pigment epithelial cells. J Cell Mol Med (2008) 1.14
Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis. Vaccine (2011) 1.12
Complement activation associates with saccular cerebral artery aneurysm wall degeneration and rupture. Neurosurgery (2006) 1.11
Comparison of surface recognition and C3b binding properties of mouse and human complement factor H. Mol Immunol (2005) 1.10
Characterization of complement factor H binding to Yersinia enterocolitica serotype O:3. Infect Immun (2008) 1.10
Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children. Clin Diagn Lab Immunol (2002) 1.08
Yin and Yang: complement activation and regulation in Alzheimer's disease. Prog Neurobiol (2003) 1.08
Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form. Eur J Immunol (2004) 1.07
Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine (2005) 1.06
Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis. Infect Immun (2005) 1.06
Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine (2003) 1.05
Interaction of pneumococcal histidine triad proteins with human complement. Infect Immun (2010) 1.05
The capsular serotype of Streptococcus pneumoniae is more important than the genetic background for resistance to complement. Infect Immun (2010) 1.05
Microbial complement inhibitors as vaccines. Vaccine (2008) 1.05
Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect Immun (2009) 1.04
Complement C3 contributes to ethanol-induced liver steatosis in mice. Ann Med (2006) 1.03
Pneumococcal carriage and acute otitis media induce serum antibodies to pneumococcal surface proteins CbpA and PhtD in children. Vaccine (2009) 1.03
Multifactor effects and evidence of potential interaction between complement factor H Y402H and LOC387715 A69S in age-related macular degeneration. PLoS One (2008) 1.03
Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology (2012) 1.02
Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Infect Immun (2007) 1.01
Anti-PsaA and the risk of pneumococcal AOM and carriage. Vaccine (2003) 1.01
Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. Pediatr Infect Dis J (2004) 1.01
Activation of complement components and reduced regulator expression in alcohol-induced liver injury in the rat. Clin Immunol (2002) 1.00
Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal capsular polysaccharides in children. J Infect Dis (2002) 1.00
Expression of complement factor H binding immunoevasion proteins in Borrelia garinii isolated from patients with neuroborreliosis. Eur J Immunol (2005) 1.00
Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera. Clin Vaccine Immunol (2010) 0.99
The surface protease PgtE of Salmonella enterica affects complement activity by proteolytically cleaving C3b, C4b and C5. FEBS Lett (2007) 0.99
Functional mapping of YadA- and Ail-mediated binding of human factor H to Yersinia enterocolitica serotype O:3. Infect Immun (2008) 0.99
Antibodies to pneumococcal proteins PhtD, CbpA, and LytC in Filipino pregnant women and their infants in relation to pneumococcal carriage. Clin Vaccine Immunol (2009) 0.99
Interaction with C4b-binding protein contributes to nontypeable Haemophilus influenzae serum resistance. J Immunol (2007) 0.99
Complement factor H as a marker for detection of bladder cancer. Clin Chem (2005) 0.98
Evolution of conjugate vaccines. Expert Rev Vaccines (2002) 0.98
Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines. Clin Vaccine Immunol (2010) 0.98
Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. J Pediatr (2010) 0.98
Complement system becomes activated by the classical pathway in intracranial aneurysm walls. Lab Invest (2009) 0.97
Factor H binding as a complement evasion mechanism for an anaerobic pathogen, Fusobacterium necrophorum. J Immunol (2008) 0.97
The group B streptococcal beta and pneumococcal Hic proteins are structurally related immune evasion molecules that bind the complement inhibitor factor H in an analogous fashion. J Immunol (2004) 0.97
Binding of the complement inhibitor C4b-binding protein to Lyme disease Borreliae. Mol Immunol (2009) 0.97
Interdomain contact regions and angles between adjacent short consensus repeat domains. J Mol Biol (2004) 0.97
Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS. Hum Mol Genet (2009) 0.96
C-reactive protein binds to the 3beta-OH group of cholesterol in LDL particles. Biochem Biophys Res Commun (2005) 0.96